Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned an average rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.00.

Several analysts have recently issued reports on PYXS shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Monday, May 19th. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th.

Pyxis Oncology Price Performance

Shares of PYXS opened at $1.23 on Thursday. The firm has a market cap of $76.20 million, a PE ratio of -1.19 and a beta of 1.15. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39. The stock’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.50.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Sell-side analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after acquiring an additional 9,062 shares during the period. Commonwealth Equity Services LLC increased its holdings in Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after acquiring an additional 10,000 shares during the period. Barclays PLC lifted its stake in Pyxis Oncology by 20.2% in the 4th quarter. Barclays PLC now owns 77,013 shares of the company’s stock worth $121,000 after purchasing an additional 12,924 shares in the last quarter. ProShare Advisors LLC bought a new position in Pyxis Oncology in the 4th quarter valued at $26,000. Finally, Jane Street Group LLC boosted its holdings in Pyxis Oncology by 36.6% in the 4th quarter. Jane Street Group LLC now owns 67,686 shares of the company’s stock valued at $106,000 after purchasing an additional 18,128 shares during the period. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.